1. Home
  2. TRVG vs AUTL Comparison

TRVG vs AUTL Comparison

Compare TRVG & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

SELL

Current Price

$4.23

Market Cap

282.2M

Sector

Technology

ML Signal

SELL

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.09

Market Cap

335.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVG
AUTL
Founded
2005
2014
Country
Germany
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.2M
335.4M
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
TRVG
AUTL
Price
$4.23
$1.09
Analyst Decision
Hold
Strong Buy
Analyst Count
5
9
Target Price
$5.28
★ $8.36
AVG Volume (30 Days)
73.0K
★ 2.5M
Earning Date
11-03-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $10,120,000.00
Revenue This Year
$15.51
$101.75
Revenue Next Year
$10.60
$29.27
P/E Ratio
$16.98
★ N/A
Revenue Growth
N/A
★ 496.00
52 Week Low
$2.59
$1.07
52 Week High
$6.80
$2.58

Technical Indicators

Market Signals
Indicator
TRVG
AUTL
Relative Strength Index (RSI) 53.91 21.80
Support Level $2.72 N/A
Resistance Level $5.77 $1.71
Average True Range (ATR) 0.27 0.11
MACD 0.12 -0.02
Stochastic Oscillator 90.95 3.45

Price Performance

Historical Comparison
TRVG
AUTL

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: